Cumberland Pharma reports Q2 revenue up 10% YoY; YTD revenue +23%

CUMBERLAND PHARMACEUTICALS INC

2025-Q2 EPS reported $0.03 revenue$22,550,418

Q2 net revenue $10.8M (+10% YoY); YTD net revenue $22.6M (+23%).
Q2 net loss $741k; YTD net income $516k; adjusted YTD EPS $0.18.
Ifetroban Phase II DMD trial showed 5.4% improvement in cardiac function; FDA submission completed.
Vibativ 4-vial starter pak now available via Vizient, covering >65% of U.S. acute care providers.
Cash and equivalents $16M; total assets $68M; shareholders' equity $28M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.